The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced colorectal cancer.  As part of the study, an analysis was conducted to assess the adverse events of special interest associated with fruquintinib treatment. Cathy Eng, MD, FACP, FASCO, from Vanderbilt Health, played a pivotal role … Continue reading Phase 3 FRESCO-2 Trial Analysis of Fruquintinib mCRC